Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis | Zendy

Kong Qing-xin | Zendy; Qiao Ruan | Zendy; Fan Cheng | Zendy; Bilin Liu | Zendy; Li-Ping Reng | Zendy; Weiping Xu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the risk of fracture in type 2 diabetes mellitus patients with incretins: an updated meta-analysis

Author(s) -

Kong Qing-xin,

Qiao Ruan,

Fan Cheng,

Bilin Liu,

Li-Ping Reng,

Weiping Xu

Publication year - 2021

Publication title -

endokrynologia polska

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.413

H-Index - 27

eISSN - 2299-8306

pISSN - 0423-104X

DOI - 10.5603/ep.a2021.0031

Subject(s) - sitagliptin , medicine , liraglutide , incretin , meta analysis , type 2 diabetes mellitus , type 2 diabetes , diabetes mellitus , sitagliptin phosphate , subgroup analysis , randomized controlled trial , publication bias , endocrinology

The effect of incretins including dipeptidyl peptidase 4 inhibitors (DPP4-Is) and glucagon-like peptide1 receptor agonists (GLP1-ras) in the treatment of type 2 diabetes increasing the risk of fracture remains controversial. No meta-analysis has been written to discuss this from the prospective interventional studies. The objective was to evaluate the association between the use of incretins and fracture risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research